Aubrak is committed to the discovery, development, and commercialization of innovative therapeutics for cancers and infectious diseases by utilizing proteolysis targeting chimera (PROTAC) technology with tissue-specific E3 ligases. We focus on the unmet medical needs, particularly on "undruggable" therapeutic targets, and deploy multiple drug discovery pipelines with great potential in clinical significance and market value. Our founders had been working in multinational pharmaceutical companies for over decades, led and participated in dozens of drug discovery and development projects, and held an in-depth understanding of the key steps throughout the entire process of drug discovery and development.